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Abstract
The Hippo signaling pathway controls organ development and is also known, in cancer, to have a tumor suppressing role.
Within the Hippo pathway, we here demonstrate, in human gliomas, a functional interaction of a transmembrane protein,
prostate transmembrane protein, androgen induced 1 (PMEPA1) with large tumor suppressor kinase 1 (LATS1). We show
that PMEPA1 is upregulated in primary human gliomas. The PMEPA1 isoform PMEPA1a was predominantly expressed in
glioma specimens and cell lines, and ectopic expression of the protein promoted glioma growth and invasion in vitro and in
an orthotopic xenograft model in nude mice. In co-immunoprecipitation experiments, PMEPA1a associated with the Hippo
tumor suppressor kinase LATS1. This interaction led to a proteasomal degradation of LATS1 through recruitment of the
ubiquitin ligase, neural precursor cell expressed, developmentally downregulated 4 (NEDD4), which led to silencing of
Hippo signaling. Alanine substitution in PMEPA1a at PY motifs resulted in failed LATS1 degradation. Targeting of a
downstream component in the Hippo signaling pathway, YAP, with shRNA, interfered with the growth promoting
activities of PMEPA1a in vitro and in vivo. In conclusion, the presented work shows that PMEPA1a contributes to glioma
progression by a dysregulation of the Hippo signaling pathway and thus represents a promising target for the treatment of
gliomas.
Introduction
Dysregulation of the Hippo signaling pathway represents a
common event in many cancers including glioma [1–4]. In
recent years, large tumor suppressor kinase 1/2 (LATS1/2)
and core components of Hippo signaling have received
significant attention in human cancer. Once stimulated by
upstream regulators, LATS1/2 phosphorylates YAP, lead-
ing to its cytoplasmic retention and inactivation; otherwise,
YAP translocates to the nucleus and activates transcription
of downstream proproliferative and antiapoptotic genes
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[5, 6]. LATS1 has been identified as a tumor suppressor,
and decreased expression of LATS1 has been correlated
with poor prognosis in glioma patients [7].
In a previous study, we demonstrated that LATS1 was
downregulated in astrocytoma due to promoter hyper-
methylation, and that restoration of expression induced
apoptosis in glioma cells [8]. More recent studies have
shown that key components of Hippo signaling could be
regulated by ubiquitination. A series of E3 ubiquitin
ligases has been found to regulate several of these pro-
teins, including LATS1 [9–11], LATS2 [12, 13], AMOT
[13, 14], and YAP/TAZ [15, 16]. The E3 ubiquitin ligase
neural precursor cell expressed, developmentally down-
regulated 4 (NEDD4), which recognizes a specific motif
in proteins, the PY motif, leads to ubiquitination of
LATS1/2 [11, 13]. Our recent work also illuminated a
critical role for Hippo-YAP in the development of human
glioma, which might involve regulation by proteasomal
degradation [17].
Prostate transmembrane (TM) protein, androgen
induced 1 (PMEPA1), also known as TM prostate
androgen-induced RNA, reported to be induced by tes-
tosterone or its derivatives, has been shown to have a role
in tumorigenesis [18, 19]. Additional studies have shown
that epidermal growth factor, transforming growth factor-
β (TGF-β), and mutant p53 also facilitate transcription of
PMEPA1 [20–22]. PMEPA1 is a type Ib TM protein
containing two PY motifs that interact with HECT-type
E3 ubiquitin ligases, such as NEDD4 [19]. Previous stu-
dies demonstrated that PMEPA1 is highly expressed in
many solid tumor types, such as breast [23], prostate [18],
lung [24], and ovarian cancers [20], but that it is difficult
to detect in leukemias and lymphomas [25]. A number of
studies have shown that PMEPA1 induces degradation of
several proteins critical to the development of cancer,
such as androgen receptor [26], TGF-β type I receptor
[24], Smad 2/3 proteins [27], and c-Maf [28]. Thus,
PMEPA1 could potentially act as a tumor suppressor gene
or an oncogene.
Based on this prior knowledge, our aim was to unravel
the underlying mechanisms of PMEPA1 function in human
glioma progression. In this study, we show that the
PMEPA1 protein is overexpressed in primary human
glioma tissues and cell lines relative to nonneoplastic brain
tissue samples and normal human astrocytes (NHA), where
PMEPA1a is the predominant isoform in glioma samples
and cell lines. The protein displayed a growth promoting
activity in vitro and in vivo, and was found to interact
directly with components of the tumor suppressing Hippo
signaling pathway. Our results identify a role of PMEPA1a
in the dysregulation of Hippo signaling and as a putative
molecular target in the treatment of human glioblastomas
(GBMs).
Results
PMEPA1 protein is overexpressed in human gliomas
We found that PMEPA1 protein levels were increased in
high grade gliomas (WHO III–IV; n= 40) relative to nor-
mal brain tissues (n= 6) and low grade gliomas (WHO II;
n= 20; Fig. 1a, b). Western blotting of lysates prepared
from primary tumors (n= 16; WHO grades II–IV) and
nonneoplastic brain tissue samples (n= 4) also confirmed
PMEPA1 overexpression in human gliomas (Fig. 1c), but
no significant correlation with IDH1 status. High expression
(IHC score > 2) was observed in 4 of 20 low grade gliomas
(WHO II; 20%), and 24 of 40 high grade gliomas (WHO
III–IV; 60%), and was therefore significantly correlated
with increasing tumor grade (Supplementary Table S1, P=
0.0034). PMEPA1 protein levels were also increased in
glioma cell lines relative to NHA in culture, except in the
case of U87MG, where PMEPA1 were nearly undetectable
(NHA; Fig. 1d).
PMEPA1a is more highly expressed in glioma tissues
and cell lines than other alternatively spliced
PMEPA1 isoforms
Four alternatively spliced isoforms exist for the PMEPA1
gene (isoforms PMEPA1a-d), and the membrane-bound
proteins (isoforms PMEPA1a, b, d) have been shown to
exhibit oncogenic functions in prostate cancer cells and
solid tumors, while cytosolic protein (isoform c) has no
effect on cancer progression [27, 29]. We therefore eval-
uated expression levels of the PMEPA1 isoforms in our
glioma cell lines, using PCR primers specific for PMEPA1a,
PMEPA1b, PMEPA1c, and PMEPA1d transcripts. PME-
PA1a was the most highly expressed isoform, with a rela-
tive expression level > 5× higher than the other isoforms in
U251, A172, and GBM#P3 cells. In U87MG cells, the
PMEPA1d isoform was more highly expressed than others
although overall relative levels were still quite low (Fig. 1e).
We also assessed expression levels of PMEPA1 isoforms in
a cohort of primary glioma and nonneoplastic brain tissue
samples. The relative levels of PMEPA1a in the tumor
samples (n= 9) was higher than in normal brain tissues
(n= 3; Fig. 1f). PMEPA1a may therefore be the isoform
with the most significant role in glioma progression.
PMEPA1a promotes glioma cell growth, migration,
and invasion both in vitro and in vivo
We first examined the efficiency of our constructs for
PMEPA1a shRNAs and ectopic expression of the various
isoforms. We used two shRNAs to target PMEPA1a, and
both led to a ~4× decrease in protein and mRNA levels as
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assessed by western blots and qRT-PCR in A172 and U251.
Constructs for isoform PMEPA1a was efficiently expressed
in U87MG cells (Supplementary Fig. S1A, B).
Growth was significantly decreased in A172- and U251-
sh-PMEPA1a cells, but enhanced in U87MG-PMEPA1a
cells (Fig. 2a). The results were corroborated in colony
forming assays (Fig. 2b; Supplementary Fig. S2A); the
number of colonies was reduced by ~50% in A172- and
U251-sh-PMEPA1a cells, but increased ~30% in U87MG-
PMEPA1a cells. Finally, migration and invasion were
decreased in A172- and U251-sh-PMEPA1a cells, but
enhanced in U87MG-PMEPA1a (~30%; Fig. 2c and Sup-
plementary Fig. S2B).
Modified cells were also orthotopically implanted into
the brains of nude mice to assess in vivo growth. HE
staining revealed that U251-sh-PMEPA1a xenografts were
more circumscribed than controls, whereas U87MG-
PMEPA1a cells were more invasive (Fig. 2d). Immuno-
histochemical staining of sections also highlighted differ-
ences in growth characteristics between xenografts. Ki67, a
marker for proliferation, was positively correlated with
PMEPA1a expression levels, whereas LATS1 was nega-
tively correlated with PMEPA1a (Supplementary Fig. S2C,
D). Finally, overall survival of animals was enhanced by
PEMPA1a knockdown (median survival, 34 vs. 49 days,
U251-NC and U251-sh-PMEPA1a, respectively, P < 0.01;
Fig. 1 The levels of PMEPA1
protein and isoform are
upregulated in primary glioma
samples and cell lines.
a Immunohistochemical staining
for PMEPA1 in human glioma
and nonneoplastic brain tissue
samples. Scale bars, 100 µm.
b Bar graphs indicate scoring
performed on
immunohistochemical staining
for PMEPA1 across gliomas,
both low grade and high grade,
and nonneoplastic brain tissue
samples. Data are represented as
the mean ± SEM. c Western blot
analysis of PMEPA1 protein
levels in primary glioma tissue
samples. d Western blot analysis
of PMEPA1 protein levels in
normal human astrocytes (NHA)
and glioma cell lines. e qRT-
PCR analysis of PMEPA1
isoforms in glioma cell lines.
Relative expression levels based
on normalization with GAPDH
is plotted. PMEPA1a,
PMEPA1b, PMEPA1c, and
PMEPA1d are analyzed in
NHA, LN18, U87MG, A172,
U251, and P3 cell lines using
isoform-specific primers.
GAPDH was used for
normalization. f qRT-PCR
performed with isoform-specific
primers on RNA from primary
human glioma (n= 9) and
nonneoplastic brain tissue
samples (n= 3). Relative
expression levels of PMEPA1a,
PMEPA1b, PMEPA1c, and
PMEPA1d were determined
using GAPDH for normalization
and plotted. Student’s t-test:
*P < 0.05, ***P < 0.001
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Fig. 2 PMEPA1a promotes proliferation, migration, and invasion of
glioma cells in vitro and in vivo. Cells were examined in a by CCK-8
and in b by colony forming assays. Data are represented as the mean ±
SEM. c Graphic analysis of results from transwell assays performed on
the indicated cells. Data are represented as the mean ± SEM from three
independent experiments. d Representative images of hematoxylin and
eosin-stained sections from the brains of nude mice implanted
intracranially with modified U251 cells or U87MG cells. Scale bars,
100 µm, 1000 µm. e Kaplan–Meier survival analysis performed with
survival data of mice implanted with indicated cells. Log-rank
test, P < 0.01. Student’s t-test: n.s.= not significant, *P < 0.05,
**P < 0.01
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Fig. 2e), but decreased in tumor bearing animals from the
U87MG-PMEPA1a group (median survival, 30 vs. 25 days,
U87MG-NC and U87MG-PMEPA1a, respectively, P <
0.01; Fig. 2e). All together, these results indicated that
PMEPA1a promoted glioma progression in vivo.
LATS1 is a PMEPA1a-interacting protein
To delineate the pathway(s) involved in the PMEPA1a
response, we performed co-immunoprecipitation (Co-IP)
assays to identify partners of the protein in human gliomas.
U87MG cells were transfected with Flag-tagged PMEPA1a or
control vector (Flag-empty-vector), and Co-IP assays were
performed followed by proteomic analysis of the isolated
PMEPA1a-associated protein complexes (Supplementary Fig.
S3A, B). Mass spectrometry revealed known PMEPA1a-
interacting proteins, such as NEDD4, but also some novel
proteins. According to TCGA database, MYH9, DHX9,
DDB1, and HMGB1 do not show distinct expression levels
between nonneoplastic and GBM samples (Data not shown
here), while VDAC1 had been reported to play a role in GBM
cell metabolism and MTA2 expression level was related to
glioma cells proliferation and invasion [30, 31]. Interestingly,
LATS1, a key component of the Hippo pathway, was also
one of the top interacting proteins. According to our previous
study, Hippo signaling pathway is of vital importance to
maintain malignant behaviors of glioma cells and worthy
investigating further [17]. Therefore, we select LATS1 kinase
as our main point in the mechanical study.
To verify the interaction between PMEPA1a and the
LATS1 kinase, we simultaneously expressed Flag-tagged
PMEPA1a and Myc-tagged LATS1 in HEK293 cells. In
these cells, we could confirm an interaction between Flag-
PMEPA1a and Myc-LATS1, where the Co-IP was per-
formed with the Flag or the Myc antibody (Fig. 3a). We also
confirmed the existence of endogenous complexes con-
taining PMEPA1 and LATS1 in U251 and U87MG cells
(Fig. 3b, c). Complexes brought down with either PMEPA1
or LATS1 antibody contained both proteins.
To map the binding region for LATS1 and PMEPA1a,
deletion mutants of LATS1 and PMEPA1a were constructed
and expressed in cells. The results indicated that amino acids
100–165 in PMEPA1a were necessary for binding to LATS1,
whereas amino acids 351–700 in LATS1 constituted the
PMEPA1a-interacting domain (Fig. 3d, e).
PMEPA1a regulates the Hippo kinase signaling
pathway
LATS1 is a tumor suppressor in the Hippo signaling path-
way and inactivates the oncogenic transcriptional regulator
YAP through phosphorylation at ser-127 [1, 15]. Loss of
LATS1 can lead to a corresponding increase in YAP
activity. Western blot analysis revealed decreased LATS1
protein levels in U87MG-PMEPA1a cells. In contrast,
LATS1 was increased in A172- and U251-sh-PMEPA1a
cells (Fig. 4a). Thus, PMEPA1a suppressed LATS1 protein
in glioma cells with an endogenous PMEPA1a expression.
Furthermore, altered PMEPA1a also led to detectable
changes in YAP and its activity. Nuclear localization of YAP
was enhanced in U87MG-PMEPA1a cells and decreased in
A172- and U251-sh-PMEPA1a cells (Fig. 4b, c). These
results are consistent with an activation of YAP through
increased PMEPA1a. Indeed, analysis of the transcriptional
activity of YAP supported this hypothesis. We demonstrated
increased YAP activity in the presence of PMEPA1a through
a YAP promoter reporter luciferase construct and qRT-PCR
of YAP endogenous downstream genes (Fig. 4d–f). These
data together demonstrate that PMEPA1a increases YAP
activity by decreasing LATS1 protein levels.
PMEPA1a promotes proteasomal degradation of
LATS1
Altered expression of PMEPA1a had no obvious effects on
mRNA levels of LATS1 (Fig. 4e, f). Therefore, we tested
whether PMEPA1a modulates LATS1 protein stability. We
first examined LATS1 protein levels in modified cell lines
treated with the proteasome inhibitor MG132. We found
that MG132 partially reversed the downregulation of
LATS1 protein in U87MG- and HEK293-PMEPA1a cells
(Fig. 5a). In addition, the half-life of LATS1 protein was
altered in these cells. In the presence of the protein synthesis
inhibitor cycloheximide (CHX), we found the half-life of
LATS1 to be reduced in U87MG- and HEK293-PMEPA1a
cells (Fig. 5b, c, f, g). In contrast, the half-life of LATS1
protein was prolonged in A172- and U251-sh-PMEPA1a
cells (Fig. 5d, e, h, i). Thus, PMEPA1a promotes
proteasome-mediated degradation of LATS1.
Levels of LATS1 ubiquitination were also consistent with
increased proteasomal degradation. In HEK293-Flag-
PMEPA1a cells expressing HA-Ub, ubiquitination of
LATS1 was increased (Fig. 5J). Furthermore, endogenous
ubiquitination of LATS1 was regulated through PMEPA1a.
In U251-sh-PMEPA1a cells, the polyubiquitination of
LATS1 was reduced, while in U87MG-PMEPA1a cells, the
polyubiquitination of LATS1 was increased (Fig. 5k, l).
Taken together, PMEPA1a plays a critical role in regulating
the protein levels of LATS1 mediated by proteasomal
degradation.
PMEPA1a destabilizes LATS1 through the E3 ligase
NEDD4
Previous studies have demonstrated that PMEPA1 med-
iates protein degradation through its natural protein
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Fig. 3 PMEPA1a physically interacts with LATS1. Co-
immunoprecipitations performed and analyzed in a–c western blot-
ting to detect interaction between PMEPA1a and LATS1 in HEK293
cells transfected with Myc-tagged LATS1 and Flag-tagged PMEPA1a,
and in parental U87MG and U251 cells. d Schematic representation of
wild-type PMEPA1a and the indicated deletion mutants. Western blot
analysis of co-immunoprecipitations performed on lysates prepared
from HEK293 cells transfected with Myc-LATS1 alone or together
with indicated Flag-PMEPA1a constructs. Upper panels represent
Co-IP performed with anti-Flag; lower panels represent total protein.
e Schematic representation of wild-type LATS1 and the indicated
deletion mutants. Western blot analysis of co-immunoprecipitations
performed on lysates prepared from HEK293 cells transfected with
Flag-PMEPA1a alone or together with indicated Myc-LATS1 con-
structs. Upper panels represent Co-IPs performed with anti-MYC;
lower panels represent total protein. Experiments were performed in
triplicate
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partner, NEDD4 [26, 28]. As LATS1 was recently iden-
tified as a novel substrate of NEDD4 [11, 13], we there-
fore performed Co-IPs to determine the relationship
between these three proteins. HEK293 cells were
transfected with increasing levels of Flag-PMEPA1a, and
Co-IPs were performed on lysates with anti-NEDD4
antibodies. Under these conditions, LATS1 complexed
with NEDD4 was increased (Fig. 6a). Co-IPs were also
Fig. 4 PMEPA1a suppresses the Hippo kinase signaling through
LATS1. a Western blot analysis to evaluate components in the Hippo
kinase pathway downstream of PMEPA1a in lysates prepared from
glioma cell lines, which were modified with PMEPA1a or sh-
PMEPA1a as indicated. β-Tubulin was used as loading control. b
Representative images of immunofluorescence staining for YAP (red)
in modified glioma cell lines showing cellular localization. Nuclei are
stained with DAPI (blue). Scale bars, 20 µm. cWestern blot analysis of
cytoplasmic (C) and nuclear (N) fractions prepared from indicated
cells. d Luciferase assay for 8xGTIIC-Lux or control reporter con-
structs indicating YAP-dependent transcriptional activity in modified
U87MG and U251 cells. Data are normalized to a Renilla reporter and
to the NC group. e, f qRT-PCR analysis of modified U87MG and
U251 cells. GAPDH was used as loading control. Data are normalized
to the NC group. Student’s t-test: *P < 0.05, **P < 0.01, ***P < 0.001
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performed with lysates prepared from U251-sh-PMEPA1a
and U87MG-PMEPA1a cells. In the absence of PME-
PA1a in U251-sh-PMEPA1a, the amount of LATS1
complexed with NEDD4 was decreased (Fig. 6b). How-
ever, with increased expression of PMEPA1a in U87MG
cells, the amount of LATS1 complexed with NEDD4 was
increased (Fig. 6c). Thus, an increase or a decrease in the
levels of PMEPA1a produced a corresponding increase or
decrease in the amount of LATS1 in complex with
NEDD4.
Fig. 5 PMEPA1a destabilizes LATS1 proteins. aWestern blot analysis
to evaluate LATS1 levels in U87MG- and HEK293-NC and -PME-
PA1a cells after treatment with proteasome inhibitor MG132 (20 µM)
for 8 h. β-tubulin was used as the loading control. b–e Western blot
analysis of LATS1 protein in modified HEK29, U87MG, A172, and
U251 cells treated with cycloheximide (CHX; 25 µg/mL) for the
indicated time. (f–i) Line graphs representing LATS1 levels
normalized to β-tubulin and to 0 h at the indicated time points from
CHX experiments (n= 4). Data are represented as the mean ± SEM.
(j–l) Western blot analysis of ubiquitination assays. Cells were
transfected with PMEPA1a in HEK293 and U87MG or shRNA (sh-
PMPA1a) in U251 cells. Cells were treated with MG132 (20 µM) for
8 h. Student’s t-test: *P < 0.05, **P < 0.01
J. Ji et al.
To further confirm that PMEPA1a regulates the level of
LATS1 through NEDD4-mediated proteasomal degrada-
tion, the PMEPA1a mutant (MT; Y161/232A), which
exhibits nearly undetectable binding to NEDD4, was
transfected into U87MG and HEK293 cells (Supplementary
Fig. S4A). On western blot, levels of LATS1 did not
decrease in the presence of PMEPA1a MT (Fig. 6d) even
though this mutant retained LATS1-binding ability (Sup-
plementary Fig. S5A, B). Ubiquitination of LATS1 was
also not increased in the presence of transfected PMEPA1a
MT (Fig. 6e). Alternatively, knockdown of NEDD4 with a
small interfering RNA (si-NEDD-2; Supplementary Fig.
S6A–C) produced similar results; wild-type PMEPA1a
failed to lead to reduced LATS1 protein levels (Fig. 6d) or
increased polyubiquitination (Fig. 6e). Two constructs for
PMEPA1a mutants, PMEPA1a-Y161/232A and PME-
PA1a-Δ100-165aa, were efficiently expressed in U87MG
cells (Supplementary Fig. S7A). Cell growth was markedly
Fig. 6 PMEPA1a promotes ubiquitination of LATS1 by facilitating its
interaction with NEDD4. a Western blot analysis of co-
immunoprecipitations performed with anti-NEDD4 and lysates pre-
pared from HEK293 cells transfected with increasing amounts of Flag-
PMEPA1a. Top panel corresponds to western blot for co-IPs; bottom
panel corresponds to total protein in lysates. Cells were pretreated with
MG132 (20 µM) for 8 h. b, c Western blot analysis of co-
immunoprecipitations performed with anti-NEDD4 and lysates pre-
pared from modified U87MG and U251 cells. Cells were pretreated
with MG132 (20 µM) for 8 h. d Western blot analysis of lysates pre-
pared from cells 48 h after transfection as indicated. U87MG cells
were transfected with Flag-PMEPA1a wild type (WT) alone, Flag-
PMEPA1a mutated (MT) alone, or with siNEDD4 as indicated.
HEK293 cells were transfected with Myc-LATS1, Flag-PMEPA1a
(WT) alone, Flag-PMEPA1a (MT) alone, or with siNEDD4 as indi-
cated. e Western blot analysis of ubiquitination assays. U87MG cells
were transfected with Flag-PMEPA1a (WT) alone, Flag-PMEPA1a
(MT) alone, or with siNEDD4. HEK293 cells were transfected with
Myc-LATS1, Flag-PMEPA1a (WT) alone, Flag-PMEPA1a (MT)
alone, or with siNEDD4. f Western blot analysis of total protein in
lysates prepared from HEK293 cells transfected with Myc-LATS1
(MT) alone, or together with Flag-PMEPA1a (WT). g Western blot
analysis of ubiquitination assays. Lysates were prepared from HEK293
cells transfected with Myc-LATS1 (MT) alone, or together with Flag-
PMEPA1a (WT)
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enhanced in U87MG-PMEPA1a cells, but remained
unchanged in U87MG-PMEPA1a-Y161/232A or PME-
PA1a-Δ100-165aa cells compared with NC group (Sup-
plementary Fig. S7B). The results were corroborated in
colony forming assays and transwell assays (Supplementary
Fig. S7C, D). luciferase-expressing modified U87MG cells
were orthotopically implanted into the brains of nude mice
to assess in vivo growth. In vivo bioluminescence revealed
that ectopic expression of PMEPA1a in U87MG cells led to
increased cell growth in vivo and reduced the survival time
of tumor bearing mice (~25 vs. 30 days, PMEPA1a vs. NC,
P < 0.05), while PMEPA1a-Y161/232A or PMEPA1a-
Δ100-165aa had no effect on cell growth, and overall sur-
vival remained unchanged in these two groups compared
with NC group either (33 or 30 vs. 30 days, PMEPA1a-
Y161/232A or PMEPA1a-Δ100-165aa vs. NC, P= n.s.;
Supplementary Fig. S7E–G).
To further validate this mechanism, a LATS1 mutant
(LATS1 MT; Y376/559A), which is insensitive to NEDD4-
mediated proteasomal degradation, was transfected into
HEK293 cells along with PMEPA1a (Supplementary Fig.
S4B). We found that although LATS1 MT was still able to
associate with PMEPA1a (Supplementary Fig. S5A, B),
LATS1 MT protein levels remained unchanged (Fig. 6f).
Ectopic expression of PMEPA1a also did not result in
increased polyubiquitination of LATS1 MT, which further
corroborated the absence of an interaction with NEDD4
(Fig. 6g).
These results suggested that the interaction between
PMEPA1a and NEDD4 was essential for regulating
LATS1. Moreover, the effect of PMEPA1a on LATS1
protein could be abrogated by deletion of NEDD4.
The Hippo pathway mediates PMEPA1a signaling
To examine whether the Hippo pathway is downstream of
PMEPA1a, we manipulated LATS1 and YAP levels using
shRNAs and expression constructs in U251-sh-PMEPA1a
or U87MG-PMEPA1a cells (Supplementary Fig. S8A) and
assessed characteristics in growth curves, colony forming
assays, and migration assays. The expression construct for
YAP contained a constitutively active form of the protein
due to mutations in the inhibitory LATS1/2 phosphorylation
sites [15]. Growth was inhibited in U251-sh-PMEPA1a
cells relative to controls, but knockdown of LATS1 or
overexpression of YAP (YAP-5SA) in these cells enhanced
growth and migration (Supplementary Figs. S8B–D; S9A,
B). However, in U87MG-PMEPA1a cells, lentivirus
expressing LATS1 or shRNA targeting YAP reduced
cell growth and migration (Supplementary Figs. S8B–D;
S9A, B).
In a subcutaneous tumor model, the oncogenic effect of
PMEPA1a on glioma growth was also shown to be
mediated by Hippo signaling/YAP. Tumor growth of U251-
sh-PMEPA1a cells increased with knockdown of LATS1 or
overexpression of YAP (Supplementary Figs. S8E; S9C,
D). In contrast, tumor growth of U87MG-PMEPA1a cells
was decreased with overexpression of the tumor suppressor
LATS1 or knockdown of YAP (Supplementary Figs. S8E;
S9C, D). Collectively, these data demonstrated that the
Hippo-LATS1-YAP axis might play a functional role in
PMEPA1a-induced the development of human glioma.
Data from experiments on immortal GBM cell lines do
not fully mimic the tumor heterogeneity observed in GBM
patients. Thus, we performed additional experiments using
GBM#P3 cells, which more faithfully retain the genetic
features of the matching primary GBM [32]. In Co-IPs,
PMEPA1 was also found to interact with LATS1 (Fig. 7a).
In western blots, LATS1 protein levels increased in
GBM#P3-sh-PMEPA1a cells as well as phosphorylated
YAP (Fig. 7b). Knockdown of PMEPA1a in GBM#P3 cells
also led to decreased cell growth in vitro (Fig. 7c) and
in vivo (Fig. 7d, e), and prolonged the survival time of
tumor bearing mice (~28 vs. 34 days, control vs. PMEPA1a
knockdown; Fig. 7f).
Finally, in primary human glioma samples, IHC scores
for PMEPA1 negatively correlated with scores for LATS1
(P < 0.01) and positively correlated with scores for CYR61
(P < 0.05), indicating a possible relationship between the
proteins, while no significant correlation was found between
PMEPA1 and p-YAP (Ser127) (Fig. 7g, h). These results
are in agreement with our proposed mechanism for PME-
PA1a, which could downregulate the protein levels of
LATS1 and then play an oncogenic role in human gliomas.
Discussion
Here, we identified the functional roles of the PMEPA1a
isoform in glioma progression and a pathway mediating its
activity. Our data show that the PMEPA1a isoform is highly
expressed in human gliomas, and overexpression of the
protein enhanced growth characteristics of glioma cell lines
in vitro and in vivo. PMEPA1a promotes LATS1 ubiquiti-
nation and degradation by recruiting the E3 ligase NEDD4,
which leads to inhibition of Hippo signaling and activation
of the growth promoting gene YAP. PMEPA1a therefore
has a putative oncogenic role in human gliomas.
Previous studies have already revealed the different roles
of PMEPA1 in various cancers [18–25]. In our study, we
performed both gain- and loss-of-function experiments
in vitro and in vivo to demonstrate that PMEPA1 plays an
oncogenic role in glioma progression. We found that
PMEPA1a interferes with Hippo signaling by directly
interacting with LATS1, which enables association with
NEDD4 and subsequent proteasomal mediated degradation.
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LATS1 protein did not show being degraded when PY
motifs of PMEPA1a were mutated or in the absence of
NEDD4. These results corroborate previous studies
reporting failure of LATS1 to interact with NEDD4 mutated
at PY motifs and thus, decreased proteasomal degradation
[11]. We found that PMEPA1a also failed to regulate
Fig. 7 PMEPA1a knockdown
inhibits glioma growth in
GBM#P3 cells in vitro and
in vivo. a Co-
immunoprecipitations to
demonstrate association of
PMEPA1a with LATS1 in
GBM#P3 cells. b Western blot
analysis to evaluate components
of the Hippo kinase pathway in
lysates prepared from GBM#P3-
NC and -sh-PMEPA1a cells.
β-tubulin was used as loading
control. c Absorbance values
(450 nm) obtained from the
CCK8 assay performed on
GBM#P3-NC and -sh-
PMEPA1a cells. Data are
represented as the mean ± SEM.
d, e In vivo bioluminescent
images and quantification of
GBM#P3-NC and -sh-
PMEPA1a derived xenografts at
the indicated time points.
f Kaplan–Meier survival
analysis performed with survival
data from mice implanted with
GBM#P3-NC and -sh-
PMEPA1a cells. Log-rank test,
P < 0.01. g Representative
images of IHC staining of
PMEPA1 and LATS1 in
primary human glioma tissue
samples. Scale bars, 50 μm.
h Correlation analysis for
PMEPA1 with LATS1 in
primary human glioma samples
based on IHC scoring. IHC
scores are indicated in
parentheses. χ2-test, P= 0.0020.
Student’s t-test: n.s.= not
significant, *P < 0.05, **P <
0.01, ***P < 0.001
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LATS1 mutated at PY motifs. This finding is consistent
with a previous study, in which PY-mutated or PY-deleted
PMEPA1 loses its ability to promote c-Maf degradation
[28]. These results are consistent with the formation of a
PMEPA1a/NEDD4/LATS1 complex, which induces poly-
ubiquitination and finally degradation of LATS1.
However, how PMEPA1 isoform a had a significant
oncogenic function in glioma is not clear. Potential expla-
nation may be based on two critical factors. Firstly, the
transmembrane (TM) domain is essential for PEMPA1
activities [27, 28] and secondly, NEDD4 is activated at the
plasma membrane by phosphorylation or other factors
[14, 33]. Based on our data, we propose the following
model (Fig. 8). Membrane-bound PMEPA1, which pos-
sesses an N-terminal region, similar to isoform c, but also a
TM domain, recruits NEDD4 to the inner side of the plasma
membrane where it can be more easily activated. Activated
NEDD4 induces LATS1 ubiquitination and degradation.
We also found that amino acids 100–165 of PMEPA1a
contain the PY motif closest to the TM domain, and may be
responsible for the interaction between PMEPA1a and
LATS1. We propose that membrane-bound PMEPA1 forms
a complex with NEDD4 and LATS1 near the inner side of
the plasma membrane, where activated NEDD4 interacts
with LATS1, which results in polyubiquitination and finally
degradation of LATS1. Further investigation is however
required to confirm this hypothesis.
Many studies have demonstrated that Hippo signaling,
which is often dysregulated and inactivated in many
cancers, is critical for tumor progression [34, 35]. More
recent reports revealed a set of E3 ubiquitin ligases, which
destabilize key members of the Hippo pathway,
illuminating another class of proteins with potential to
drive tumorigenesis [9–16]. Recently, we have reported
that actin-like 6A promotes YAP/TAZ protein stability by
preventing interaction with beta-TrCP, which results in
transcriptional activation of growth promoting genes
underlying glioma progression [17]. In this study, we found
that PMEPA1a regulates LATS1 protein by facilitating its
interaction with NEDD4, an E3 ubiquitin ligase, and thus
proteasomal degradation, which leads to nuclear accumula-
tion and activation of YAP. Moreover, in PMEPA1a
knockdown experiments, growth promoting activities of the
transmembrane protein could be partially restored through
manipulation of downstream components in the Hippo path-
way, indicating that the Hippo pathway is likely to mediate
the oncogenic functions of PMEPA1a in the development of
human glioma.
In conclusion, our study demonstrates that membrane-
bound PMEPA1, especially PMEPA1a, plays an oncogenic
role in glioma progression. PMEPA1a facilitates association
of LATS1 with NEDD4, which results in polyubiquitination
and proteasomal degradation. Overexpression of PMEPA1a
effectively leads to dysregulation of the Hippo pathway.
Finally, this study identifies PMEPA1a as a putative




All experiments and the use of human tissues were
approved by the Research Ethics Committee of Shandong
University (Shandong, China). Human brain tumor and
nonneoplastic tissue samples were obtained from surgeries
performed at the Department of Neurosurgery at Qilu
Hospital (Shandong, China). Informed written consent was
obtained from all patients. Normal brain tissues were
obtained from brain trauma patients who underwent partial
cerebral resection. All animal studies were approved by and
performed under the guidance of the Institutional Animal
Care and Use Committee (IACUC) of Shandong University.
Cell culture and transfection
HEK293 cells and human glioma cell lines, LN18, U87MG,
U251, and A172 were obtained from the Culture Collection
of the Chinese Academy of Sciences (Shanghai, China).
NHA and primary glioblastoma (GBM) #P3 cells were
obtained from the University of Bergen, Norway. The
plasmids used are listed in Supplementary Table S2. The
sequences of shRNAs and siRNAs used are listed in Sup-
plementary Table S3.
Fig. 8 PMEPA1a promotion of tumor progression is mediated by
Hippo signaling. PMEPA1a promotes tumor growth by facilitating
degradation of LATS1, an important tumor suppressor protein inhi-
biting activity of YAP, a transcriptional activator of growth promoting
genes. In cells overexpressing PMEPA1a, YAP is activated due to the
loss of LATS1, while PMEPA1a depletion lead to increased YAP
phosphorylation at ser-127 and foster cytoplasmic sequestration,
causing inhibited phenotypes
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Nuclear and cytoplasmatic fractionation
Nuclear and Cytoplasmic Extraction Reagents (Thermo
Fisher Scientific lnc., Waltham, MA, USA) were used to
obtain nuclear and cytoplasmic cellular subfractions
according to the manufacturer’s instructions. Subcellular
distribution of proteins, including YAP, were determined
using western blot analysis. GAPDH and Histone H3 served
as loading controls for cytosolic and nuclear protein frac-
tions. See more details in Supplementary Methods and
Materials. Experiments were performed in triplicate.
Immunohistochemistry, immunofluorescence, and
immunoblotting
Immunohistochemistry (IHC), immunofluorescence, and
immunoblotting were performed as previously described
[36]. Images were acquired using a Zeiss LSM780 confocal
microscope (Carl Zeiss Microscopy GmbH, Jena, Ger-
many). The IHC-stained samples were reviewed and eval-
uated by two blinded pathologists. Scores were determined
on a scale of 0–4 by as follows: 0, no staining; 1, weak
staining in <50% cells; 2, weak staining in ≥50% cells; 3,
strong staining in <50% cells; and 4, strong staining in
≥50% cells. Immunoblotting experiments were performed in
triplicate.
Co-immunoprecipitation (Co-IP)
Cells were lysed in RIPA buffer (Pierce; Rockford, IL,
USA) containing a protease inhibitor cocktail (Sigma).
Total protein (200 µg; 1 µg/µL) was incubated with primary
antibodies (4 µL) or IgG (4 µL) overnight at 4 °C with
gentle shaking and then Protein A/G magnetic beads
(Thermo Fisher Scientific) for 2 h at room temperature. The
immunoprecipitated complexes were washed, boiled in
protein loading buffer, and immunoblotted or subjected to
mass spectrometry analysis (ekspertTMnanoLC; AB Sciex
TripleTOF 5600-plus; SCIEX; Redwood City, CA, USA).
Results of LC–MS/MSF were analyzed using Proteinpi-
lotTM software (SCIEX). For the ubiquitination assay, cells
were treated with 20 µM MG132 for 6 h before lysis, and
subsequent co-IP and western blot analysis.
Cycloheximide (CHX) chase
LATS1 and PMEPA1a expression plasmids were cotrans-
fected into HEK293 cells using Lipofectamine 3000
(Thermo Fisher Scientific). U87MG cells were infected with
lentivirus for ectopic expression of full-length PMEPA1a
(OBiO Technology). After 48 h, CHX (25 µg/mL) was
added to the culture medium to inhibit translation, and cells
were incubated for 0, 2, 4, or 6 h. Cell lysates were
prepared, and protein (20 µg) was examined using western
blot analysis. Experiments were performed in triplicate.
Cell migration and invasion assay
Cell migration and invasion assays were performed as
previously described [17]. Matrigel-coated (BD Bios-
ciences, Bedford, MA, USA) and uncoated transwell
chambers (pore size: 8 μm; Corning Costar, NY, USA) were
used to evaluate cell invasion and migration accordingly.
Experiments were performed in triplicate.
Cell viability assay
Cell viability assay was performed as previously described
[37]. After transfection for 48 h, cells were seeded into 96-
well plates (5 × 103 cells/well) and incubated at 37 °C
overnight. After incubation with CCK-8 solution (10 μL/
well; Dojindo; Kumamoto, Japan), the absorbance at
450 nm (OD450) was measured in a microplate reader (Bio-
Rad; Hercules, CA, USA), and the results were plotted
against time in days to generate growth curves. Experiments
were performed in triplicate.
Colony forming assay
After transfection, cells (1.0 × 103/well) were seeded into
six-well plates and cultured for an additional 2 weeks. Cells
were fixed with 4% paraformaldehyde (Solarbio; Beijing,
China) and stained with 5% crystal violet. Colonies of more
than 50 cells were counted. Experiments were performed in
triplicate.
Reverse transcription PCR
Total RNA was isolated from cells or human tissues using
Trizol Reagent (Thermo Fisher Scientific). RNA (2 µg) was
reverse transcribed into cDNA using the High Efficient
Reverse Transcription Kit (Toyobo Life Science; Shanghai,
China) according to the manufacturer’s protocol. Quantita-
tive PCR was performed using SYBR premix Ex Taq
(Takara; Tokyo, Japan) on the Real-Time PCR Detection
System (Roche, 480II; Basel, Switzerland). GAPDH served
as the internal control for normalization. Primers used for
PCR are listed in Supplementary Table S4. Experiments
were performed in triplicate.
Luciferase reporter assays
Modified U87MG and U251 cells were cotransfected with
firefly luciferase (100 ng) and renilla reporters (100 ng)
using Lipofectamine 3000 (Thermo Fisher Scientific).
Luciferase assays were performed 24 h later using the Dual-
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Luciferase Reporter Assay Kit (Promega). Renilla activity
was used to normalize luciferase reporter activity. Experi-
ments were performed in triplicate.
Animal studies
Stable transfected glioma cell populations (1 × 106 cells)
were implanted into the frontal lobes of 4-week-old nude
mice (Shanghai SLAC Laboratory Animal Co., Ltd;
Shanghai, China) using a stereotactic frame (KDS310, KD
Scientific; Holliston, MA, USA).
Luciferase-expressing GBM#P3 and U87MG cells were
implanted orthotopically in nude mice brains, and tumor
growth was examined using bioluminescence (IVIS
SPECTRUM, PerkinElmer; Hopkinton, MA, USA). The
subcutaneous GBM model was established as previously
described [17].
Statistical analysis
Data are presented as mean ± SEM. The Student’s t-test for
paired data was used to compare mean values. ANOVA was
used to analyze potential differences between two groups
with continuous variables. Survival curves were estimated
by the Kaplan–Meier method and compared using the log-
rank test. Correlation between PMEPA1 and LATS1, p-YAP
(Ser127), or CYR61 expression levels was determined using
the two-tailed χ2 test or the Fisher’s exact test. Statistical
analysis was conducted using GraphPad Prism version
7.00 software program for Windows (GraphPad; La Jolla,
CA, USA). All tests were two-sided, and P-values < 0.05
were considered to be statistically significant.
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